imatinib mesylate has been researched along with Adenocarcinoma, Mucinous in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bauerschlag, DO; Hilpert, F; Jonat, W; Maass, N; Meinhold-Heerlein, I; Mundhenke, C; Roesel, F; Schem, C; Sturner, KH; Weigel, MT | 1 |
1 other study(ies) available for imatinib mesylate and Adenocarcinoma, Mucinous
| Article | Year |
|---|---|
Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Carboplatin; Carcinoma, Papillary; Cell Proliferation; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Ovarian Neoplasms; Paclitaxel; Piperazines; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; RNA, Messenger; RNA, Neoplasm; Tissue Array Analysis; Tumor Cells, Cultured | 2008 |